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Pharmacology and Prescribing in Alcohol Misuse. 
 
Abstract 
In this article in the series of ‘bite sized’ pharmacology, we will look at the pharmacological 
actions of drugs used in the management of alcohol misuse. This article will outline the issues 
and areas of intervention required in people who misuse alcohol to the detriment of health. It 
will illustrate the common therapeutic interventions in patients who misuse alcohol and wish 
to detoxify or reduce their intake. It will then go on to examine the main types of drug used in 
these interventions and their pharmacodynamic actions. The management will be considered 
within the NICE guidance and evidence base.  
Exercises will be provided to help you apply this knowledge to your prescribing practice.  
 
Alcohol Misuse 
According to NHS Choices (2018) Alcohol misuse is the consistent and excessive drinking of 
alcohol above the low risk limits of 14 units per week. According to the Office for National 
Statistics release of 2016 figures showed; 
 7,327 alcohol-specific deaths in the UK, a rate of 11.7 deaths/ 100,000 population. 
 For the UK, the 2016 alcohol-specific deaths rate continues to remain unchanged 
since 2013, but is still higher than that observed 15 years ago. 
 Since 2001 rates of alcohol-specific deaths among males have been an average of 
55% higher than those observed among females. 
 Rates of alcohol-specific deaths are highest among those aged 55 to 64 years in 2016. 
 Scotland remains the constituent country with the highest rate of alcohol-specific 
deaths in 2016; yet Scotland has also seen the largest decrease in its rates since they 
peaked in the early 2000s. 
 In England, and for both sexes, alcohol-specific death rates in 2016 were significantly 
higher in the most deprived local areas when compared with the least deprived local 
areas. 
https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/drugusealcoholandsmok
ing/bulletins/opinionsandlifestylesurveyadultdrinkinghabitsingreatbritain/2005to2016 
 
Pharmacological Action of Alcohol and User Expectation 
Alcohol is classed as a general central nervous system depressant.  It potentiates the effects of 
gamma-aminobutyric acid (GABA), the inhibitory central nervous system (CNS) transmitter, 
in opening chloride channels which are the major inhibitory transmission pathways in the 
CNS. This is similar to effects seen with benzodiazepines. It also appears to antagonise 
effects of the excitatory neurotransmitter glutamate through NMDA receptors and promotes 
the release of endorphins and dopamine, which may go some way explain its pleasurable 
effects.  Rang, Dale, Ritter & Flower (2015) 
Alcohol causes relaxation and a feeling of general well-being.  It can also promote 
disinhibited behaviour and has been associated with risk-taking behaviour and impaired 
judgment.  The precise effects vary with the amount taken, the mood of the individual and the 
environment they are in.  It is often said that alcohol will enhance the existing mood whether 
that be high or low. These effects can be seen with occasional and low level intake but a 
tolerance (a need for more alcohol to achieve the same effect) can be seen with misuse.  
Can we have a picture here relating to alcohol? 
 
Dependency 
Alcohol causes physical as well as psychological dependency in some individuals.  
Problem drinking can be characterised by 
 Drinking more alcohol, or stronger alcohol or for longer 
 An inability to reduce intake or stop drinking despite successive attempts 
 Memory problems or blackouts 
 Absence from work due to drinking behaviour 
 Risk taking behaviour or criminal activity 
 Withdrawal symptoms from alcohol such as tremor, restlessness, nausea, sweating, 
palpitations and seizure 
 
Potential harmful effects on health 
Excessive consumption of alcohol can cause physical harm in a number of ways.  There is a 
direct toxic effect on tissues such as the brain and liver, an associated poor diet can lead to 
vitamin deficiency, notably thiamine deficiency that in the long-term causes Wernicke’s 
encephalopathy and Korsakov’s syndrome.  It can lead to an increased risk of accidents; 
especially head injury and the general self-neglect which ensues can increase an individual’s 
susceptibility to infection. 
Acute adverse effects of alcohol include behavioural disturbance, flushing, hypothermia, 
diuresis, dehydration, sedation, poor sleep, gastritis, vomiting, oesophageal reflux and 
haematemesis, hypoglycaemia and arrhythmias.  Unconsciousness can occur and death may 
result from inhalation of vomit. 
Regular, high chronic intake can lead to liver damage, gastritis, pancreatitis, hypertension and 
stroke plus an increased risk of carcinoma.  Various psychiatric disorders such as paranoia, 
depression and anxiety are also common. 
 
The primary goal of drug therapy in management of alcohol misuse is to reduce the 
likelihood of harm. This is related to the harm that the overuse of alcohol causes as well as 
any domestic, societal or criminal harm that may arise from the addictive behaviour.  The 
drugs we use help us manage the patient in the withdrawal form alcohol (or detoxification) 
stage of their treatment. 
 
Alcohol Withdrawal and its Pharmacological Management 
This is a very important area for consideration as it is the area where much of the prescribing 
in this condition occurs. Persons with significant alcohol dependence with experience 
withdrawal symptoms which are severe and serious in nature. They may even prove life 
threatening if not managed appropriately. 
They include 
 Anxiety 
 Tremor 
 Restlessness 
 Nausea 
 Sweating and or fever 
 Palpitations and tachycardia 
 Seizures 
 Delirium tremens  
Exercise 
Reflect on the common withdrawal symptoms you see in clinical practice and relate these to 
these to the pharmacological action of alcohol and how withdrawing this produces symptoms 
and effects. 
 
Pharmacological therapy for assisted alcohol withdrawal is covered in section 1.3 of the 
NICE Guidance, CG115 (2011) – Alcohol-use disorders: diagnosis, assessment and 
management of harmful drinking and alcohol dependence.  
Chlordiazepoxide- this is a long acting benzodiazepine drug which is used in assisted 
withdrawal from alcohol. It has classical benzodiazepine effects mediated through its effect 
on GABA, which reduces neuronal excitability. It is helpful in symptom control as it can 
suppress many of the symptoms we saw above but particularly useful in prevention of 
seizures. It can be used in varying doses dependent on severity of dependence and response. 
In some patients diazepam may be used and it acts in a similar fashion. Choice is often 
dictated by local protocols and may be influenced if hepatic impairment when the use of 
lorazepam, which relies less on hepatic metabolism, is a safer option.  Patients should be 
supervised through their withdrawal for possible cross tolerance of benzodiazepines with 
alcohol. 
 
Exercise 
Using pharmacologically available resources such as textbooks, the BNF or online electronic 
medicines compendium, explore the range of benzodiazepines and their indications. 
Reconcile this with your local policy on prescribing in alcohol withdrawal and NICE 
Guidance  
 
Clomethiazole- this is a barbiturate type drug that is useful in assisted withdrawal from 
alcohol. It can relieve or suppress the symptoms associate with withdrawal which related to 
central withdrawal actions and has an effect on GABA receptor action, producing 
anticonvulsant and anxiolytic effects. It is for short term use only and should only be used in 
monitored in patient settings and where the patient has no access to alcohol, as there is a risk 
of overdose and misuse. It is contraindicated in patients who continue to drink and should be 
used with extreme caution and at lower doses in hepatic impairment due to the risk of coma.  
 
Thiamine- this essential nutrient is depleted in people with chronic long term alcohol misuse. 
Thiamine deficiency is associated with an increased incidence of Wernicke’s encephalopathy 
and Wernicke- Korsakoff psychosis. Replacement of this deficiency by supplement cane 
lessen the impact of either of these alcoholic brain diseases and is an essential component of 
assisted withdrawal. Doses vary dependant on the severity of deficiency and are usually 
administered orally although parenteral formulations are available. .  
 
Drugs can continue to be used after successful withdrawal has been achieved to support the 
patents health and maintain absence or try to prevent relapse.  
 
Acamprosate- Acamprosate is useful for patients who have withdrawn from alcohol and it 
can prevent relapse. Treatment should commence as soon as abstinence has been achieved 
and continue for up to one year. It should be used with caution in hepatic impairment and 
avoided completely if this is severe in nature. Its mode of action is proposed to be at NMDA 
and GABA receptors and can reduce the craving for alcohol. Used alone it had limited 
effectiveness and should be combined with psychological support (Robertson 2016). 
 
Disulfiram- this drug is given to help achieve and maintain abstinence. When taken, if 
alcohol is imbibed while on this drug and extreme and unpleasant reaction occurs. It creates 
an acute sensitivity to alcohol by inhibition of the enzyme acetaldehyde dehydrogenase which 
metabolises the primary metabolite of alcohol- acetaldehyde- to a harmless chemical, this 
thereby reduces normal alcohol metabolism by the liver and leads to an accumulation of 
acetaldehyde giving the patient unpleasant and hangover like effects. It is for this reason it is 
sometimes referred to as aversion therapy. Symptoms occur within 10-20 minutes of 
consuming alcohol and are brought about by the accumulation of acetaldehyde which 
provokes flushing, headache, palpitations, nausea and vomiting. It is only effective if taken 
on a daily basis (Robertson 2016). 
 
Naltrexone- Naltrexone- this drug is an opioid receptor antagonist found to have benefit in 
prevention of relapse after successful alcohol withdrawal. It has been shown to decrease the 
amount and frequency of drinking (SAMHSA 2016). Care should be taken when prescribing 
for patients on opioid based analgesia as it can reduce the effectiveness of these painkillers 
(NICE 2011). 
 
Hepatic Impairment in Alcohol Misuse 
Hepatic impairment is a factor to consider when prescribing for this group of patients. 
Cirrhosis or liver disease caused by alcohol misuse reduced hepatic function and the body’s 
ability to eliminate drugs. Guidance in the BNF and other drug choice support policies should 
be followed and liver function tests carried out and monitored regularly throughout treatment.  
 
Exercise 
Using pharmacologically available resources such as textbooks, the BNF or online electronic 
medicines compendium, find out the usual doses of the drugs above that you are most likely 
to prescribe in practice. Relate any issues with potential hepatic impairment for patients with 
alcoholic liver disease and how this would impact on your prescribing practice.  
Can we have a photo of a BNF here please? 
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